Navigation Links
Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
Date:10/19/2011

that primarily causes central nervous system problems. In MS, the insulating fatty material surrounding the nerve fibers, also known as myelin, which functions to speed signaling from one end of the nerve cell to the other, is attacked by cells of the immune system causing problems in signal transduction. According to the Accelerated Cure Project for Multiple Sclerosis, a national nonprofit organization, 400,000 people in the US are affected by MS and another 2 million globally. Nutra Pharma's MS drug, RPI-78M, has shown efficacy in animal models (EAE) for MS and the Company is planning new animal studies to gain more insight into the levels of protection that the drugs afford. In one study conducted in August 2007, all members of an untreated animal control group developed signs of disease with different levels of paralysis/muscle weakness. A similar group in the August 2007 study treated with RPI-78M showed no disease in 90% of the animals in both acute and chronic applications of the test. Moreover, there were no toxicities reported though the animals received doses the equivalent of 280 times a human dose.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin™. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "a
'/>"/>

SOURCE Nutra Pharma Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Native Remedies NutraRx Brand of Natural Products for Medical Practitioners Among First to Earn Prestigious Emerson EQP Seal
2. Maxam Nutraceutics Introduces PCA-Rx as a Natural Chelation Alternative for Autism Spectrum Disorder Treatment
3. Nutraceutical Leader Announces Internal Promotions of Key Personnel
4. Synutra to Participate in Citis Greater China Investor Conference
5. Reportlinker Adds Nutraceutical Market
6. Reportlinker Adds Global Nutraceuticals Industry
7. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
8. Synutra to Announce Third Quarter Fiscal 2011 Financial Results
9. Colorcon Expands Nutraficient Product Portfolio to Include High Productivity, PVA-Based Formulations for Food Supplement Coating
10. ScienceBased Health and Hoya Surgical Optics, Inc. Combine Forces to Expand Reach of Evidence-Based Nutraceuticals in Ophthalmic Market and Enhance Patient Care
11. Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... -- Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... the fourth quarter and year ended December 31, 2014. ... less than $0.01 per share, on revenues of $8,018,000 ... with net income of $195,000, or $0.01 per share, ... 2013. The substantial increase in fourth quarter 2014 revenue ...
(Date:3/6/2015)... , March 6, 2015  AbbVie (NYSE: ... Health Care Conference on Thursday, March 12, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 2Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 3Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 4Ascendant Solutions, Inc. Reports Fourth Quarter and Year End 2014 Earnings 5TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... 5, 2012 Cogmedix , ... device companies cost effectively improve their time-to-market, partnered ... the company,s refractive cataract surgery laser system. Designed ... critical manual steps in cataract surgery, the LensAR ...
... Officer of the American Telemedicine Association, has shared ... telehealth in the immediate future.  These trends represent ... challenges and opportunities for the industry.  ... 1. A Shift away from reimbursement models ...
Cached Medicine Technology:Cogmedix Provides High-Precision Subassembly for LensAR Revolutionary Refractive Laser 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 2ATA CEO: 7 Market Trends Shaping the Future of Telemedicine 3
(Date:3/6/2015)... 06, 2015 “On Tap” takes the audience ... grand stage, to the silver screen and to modern day ... toe-tapping numbers and their famous eye-high kicks! Producers, directors and ... history of tap dancing in this robust show, showcasing one ... the United States. , “On Tap” is proud to ...
(Date:3/6/2015)... San Rafael, CA (PRWEB) March 06, 2015 ... the addition of three Maryland camps – two non-contact ... camps will be run by Perfect Performance Training, located ... camps will focus on developing position specific skills, speed ... will be hosted at Salisbury University with Marvin Graves, ...
(Date:3/6/2015)... At Natural Products Expo West, Makeena, ... of its powerful, location-aware iOS app that helps ... at any retailer that carries those products, including ... Booth 6054. , Makeena’s proprietary algorithm allows ... Paleo, and vegan, among many other product attributes. ...
(Date:3/6/2015)... Johnson & Johnson and Ethicon were hit with ... in Superior Court in the State of California in ... 12 awarded Mrs. Perry $700,000 in actual damages for ... TVT Abbrevo plastic sling for stress urinary incontinence. The ... $5 million in punitive damages. , According to court ...
(Date:3/6/2015)... First Choice Emergency Room opened ... is located at 13351 W. Bowles Avenue, Littleton, Colorado and ... ready 24-7 to provide the highest quality emergency medical care ... of First Choice Emergency Room Littleton. , First ... Metro Denver Chamber of Commerce and a medical community open ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2
... inclination, study finds , WEDNESDAY, June 17 (HealthDay News) -- Bad ... violent street gangs. But a new study finds that the urge ... genes. , Boys who have a variant of the gene monoamine ... are not only more likely to be in gangs than boys ...
... , - SLA Centennial Observance ... Century , Elsevier has been awarded ... BioMedicine and the Life Sciences" at the Special Library,Association,s (SLA) ... published by Elsevier, many on behalf of renowned,societies, were also ...
... in Health and Life Sciences Category , , SUNNYVALE, ... Incorporated (Nasdaq: ARAY ), a global leader in ... the company,s president and CEO, received the Ernst & Young ... Life Sciences category in Northern California. According to Ernst ...
... has begun , , PITTSBURGH, June 17 Mylan ... subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. ... Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This ... and 30 mg strengths of the product. , , ...
... 2009 Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) ... agreement with Deerfield Management, a leading healthcare investment organization and ... funding through a credit facility. , , "We ... the potential of our business and that we have the ...
... the development of TMC207 and the discovery of new ... 17 A new landmark collaboration between the Global ... product development partnership, and Tibotec Inc., (Tibotec), a global ... Health Summit in response to the urgent need to ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 2Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 3Health News:Elsevier Honored as "The Most Influential Publisher of the Last 100 Years in BioMedicine and the Life Sciences" by the Special Libraries Association 4Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 2Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 3Health News:Arena Pharmaceuticals to Receive $100 Million from Deerfield Management 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 2Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 3Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 4Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 5Health News:Unique Collaboration Between TB Alliance and Tibotec To Accelerate Tuberculosis Drug Development 6
... Angiotensin Converting Enzyme (ACE), also known ... (EC 3.4.15.1) with a molecular weight of ... glycoprotein shows a single polypeptide chain, a ... is present in many different cell types ...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin RIA Lipid / Protein Quantification, Cardiovascular 024-IDC-11 Muscle Disease...
Anti-Gliadin IgA (Ab) EIA Gastrointestinal Markers 027-GD17 Celiac Disease Food Allergy...
Medicine Products: